Engineers Gate Manager LP Lineage Cell Therapeutics, Inc. Transaction History
Engineers Gate Manager LP
- $4.86 Billion
- Q3 2024
A detailed history of Engineers Gate Manager LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 11,458 shares of LCTX stock, worth $7,103. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,458Holding current value
$7,103% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
95.1MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$25.8 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$5.33 Million0.0% of portfolio
-
Defender Capital, Llc.5.96MShares$3.7 Million1.17% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$3.1 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $105M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...